Overview

We aspire to enable biopharma companies to exceed their goals in developing and delivering life-transforming nucleic-acid therapies, production processes, as well as GMP manufacturing of biopharmaceutical drug substances. By collaboration with biopharma partners as well as academic institutions, sapientis is establishing a premier ecosystem to enable network effects, scientific progress, and shared learning to speed up the availability of biotechnological solutions for serious diseases within infectious diseases, onco-immunology, and precision medicine in rare diseases, concentrating on pilot projects and delivering products for clinical trial activities. sapientis is planning to start operating the state-of-the-art cGMP biotechnological pilot plant including development laboratories from Q4 2023 to provide comprehensive GMP development and the complete spectrum of services from discovery to drug substance and drug product development and manufacturing for New Biological Entities (NBEs) worldwide.